Sangamo Therapeutics (NASDAQ:SGMO) Vs. AMGN, GILD, REGN, VRTX, BIIB, SGEN, INCY, ALNY, BMRN, and EXAS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs.
Gilead Sciences (NASDAQ:GILD) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
Gilead Sciences has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Gilead Sciences has a net margin of 26.91% compared to Sangamo Therapeutics' net margin of -167.16%. Gilead Sciences' return on equity of 56.59% beat Sangamo Therapeutics' return on equity.
Gilead Sciences currently has a consensus target price of $79.18, indicating a potential upside of 15.02%. Sangamo Therapeutics has a consensus target price of $18.40, indicating a potential upside of 208.21%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Gilead Sciences.
Gilead Sciences received 1985 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 79.18% of users gave Gilead Sciences an outperform vote while only 66.20% of users gave Sangamo Therapeutics an outperform vote.
In the previous week, Gilead Sciences had 22 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 24 mentions for Gilead Sciences and 2 mentions for Sangamo Therapeutics. Gilead Sciences' average media sentiment score of 0.02 beat Sangamo Therapeutics' score of -0.21 indicating that Gilead Sciences is being referred to more favorably in the media.
78.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 52.0% of Sangamo Therapeutics shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 2.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Gilead Sciences beats Sangamo Therapeutics on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics (NASDAQ:SGMO) vs. Its Competitors
Sangamo Therapeutics Competitors List
